I-125 seeds with chemotherapy for progressive non-small-cell lung cancer after first-line treatment: a meta-analysis

被引：0
|
作者：
Zhong-Ke Chen
Jing Fan
Fen-Qiang Li
Shi-Yan Zhou
Yuan-Shun Xu
机构：
[1] Affiliated Hospital of Gansu Medical College,Department of Interventional Therapy
[2] Lanzhou University First Affiliated Hospital,Interventional Radiology Department
[3] Xuzhou Central Hospital,Radiology Department
来源：
Journal of Cardiothoracic Surgery | / 17卷
关键词：
I-125 seed; Non-small-cell lung cancer; Progressive; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis
    Joerger, M.
    Matter-Walstra, K.
    Frueh, M.
    Kuehnel, U.
    Szucs, T.
    Pestalozzi, B.
    Schwenkglenks, M.
    ANNALS OF ONCOLOGY, 2011, 22 (03) : 567 - 574
  • [42] A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression
    Herbst, Roy
    Jassem, Jacek
    Abogunrin, Seye
    James, Daniel
    McCool, Rachael
    Belleli, Rossella
    Giaccone, Giuseppe
    De Marinis, Filippo
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [43] Chemotherapy with or without pemetrexed as second-line regimens for advanced non-small-cell lung cancer patients who have progressed after first-line EGFR TKIs: a systematic review and meta-analysis
    Li, Zhihua
    Guo, Haiyan
    Lu, Yiyu
    Hu, Jianxin
    Luo, Haitao
    Gu, Weiguang
    ONCOTARGETS AND THERAPY, 2018, 11 : 3697 - 3703
  • [44] The efficacy of first-line chemotherapy is associated with KRAS mutation status in patients with advanced non-small cell lung cancer: a meta-analysis
    Yaxiong Zhang
    Wenfeng Fang
    Yue Yan
    Mengyao Wang
    Shiyang Kang
    Jin Sheng
    Jianhua Zhan
    Nan Chen
    Shaodong Hong
    Yunpeng Yang
    Yuxiang Ma
    Dacheng He
    Tao Qin
    Ting Zhou
    Yanna Tang
    Xiaobo He
    Wenhua Liang
    Li Zhang
    Medical Oncology, 2015, 32
  • [45] Pharmacoeconomic analysis of consolidation therapy with pemetrexed after first-line chemotherapy for non-small cell lung cancer
    Tsuchiya, Takanori
    Fukuda, Takashi
    Furuiye, Masashi
    Kawabuchi, Koichi
    LUNG CANCER, 2011, 74 (03) : 521 - 528
  • [46] The efficacy of first-line chemotherapy is associated with KRAS mutation status in patients with advanced non-small cell lung cancer: a meta-analysis
    Zhang, Yaxiong
    Fang, Wenfeng
    Yan, Yue
    Wang, Mengyao
    Kang, Shiyang
    Sheng, Jin
    Zhan, Jianhua
    Chen, Nan
    Hong, Shaodong
    Yang, Yunpeng
    Ma, Yuxiang
    He, Dacheng
    Qin, Tao
    Zhou, Ting
    Tang, Yanna
    He, Xiaobo
    Liang, Wenhua
    Zhang, Li
    MEDICAL ONCOLOGY, 2015, 32 (03)
  • [47] Chemotherapy with or without gefitinib in patients with advanced non-small-cell lung cancer: a meta-analysis of 6844 patients
    Zhou Hang
    Zeng Chao
    Wang Li-yang
    Xie Hua
    Zhou Jin
    Diao Peng
    Yao Wen-xiu
    Zhao Xin
    Wei Yang
    CHINESE MEDICAL JOURNAL, 2013, 126 (17) : 3348 - 3355
  • [48] Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer
    Puneet Saxena
    Pawan Kumar Singh
    Prabhat Singh Malik
    Navneet Singh
    Current Treatment Options in Oncology, 2020, 21
  • [49] Pembrolizumab in Combination with Chemotherapy as First-Line Treatment of Advanced Non-Small Cell Lung Cancer
    Jahan, N.
    Swarup, S.
    Sultan, A.
    Naing, T.
    Mogollon-Duffo, F.
    Ball, S.
    Tun, A.
    Htut, T.
    Dash, A.
    D'Cunha, N.
    Hardwicke, F.
    Awasthi, S.
    Tijani, L.
    Thein, K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S917 - S918
  • [50] Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer
    Saxena, Puneet
    Singh, Pawan Kumar
    Malik, Prabhat Singh
    Singh, Navneet
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (08)
12345